The Purpose of the COA Compendium The pilot COA Compendium (view PDF) is part of FDA’s efforts to foster patient-focused drug development. The COA Compendium is intended to facilitate communication and to provide clarity and transparency to drug developers and the research community by collating and summarizing clinical outcome assessment (COA)2 information for many different …
Author Archives: barbarabauer
Horizon Pharma Completes Acquisition of Crealta Holdings LLC
Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced that it has completed its acquisition of Crealta Holdings LLC for approximately $510 million in cash. About Horizon Pharma plc Horizon Pharma plc is a biopharmaceutical …
Continue reading “Horizon Pharma Completes Acquisition of Crealta Holdings LLC”
Sanofi Stock Update: Mergers, Licensure Agreements To Boost Company Revenue in 2016
Given a strong drug pipeline and company financials, analysts expect Sanofi stock to do well in 2016. Sanofi ADR (NYSE:SNY) shares closed down 1.68% on December 31, 2015. The stock’s beta value is 1.00. The company has a total market capitalization of $112.90 billion, with 1.31 billion outstanding shares. In terms of sales, the drugmaker …
Whitepaper: GPCR — Drug Targets
SAVE 10%! The GPCR — Drug Targets Report on G-Protein Coupled Receptors (GPCR) covers types of various GPCR Families and ligands targeting GPCR. Included are: GPCR families: Rhodopsin, Secretin, Metabotropic glutamate and much more. And, Ligands targeting GPCRs: Peptides or Proteins, Biogenic Amines, Lipids and others.
Pfizer and Allergan Merger to Create Uncertainty for Agencies, Execs Say
When Pfizer announced plans to acquire Allergan for $160 billion, the first questions to surface had to do with the feasibility of the deal. What are the tax implications? What would a combined Pfizer-Allergan look like?